BackgroundCheck.run
Search For

Rebecca K Mchugh, 66Bulls Gap, TN

Rebecca Mchugh Phones & Addresses

Bulls Gap, TN   

Watertown, MA   

Cape Coral, FL   

29 Serendipity Blvd, N Ft Myers, FL 33903    916-8350891   

2762 Providence St, Fort Myers, FL 33916   

North Fort Myers, FL   

11125 Gingerwood Way, Rncho Cordova, CA 95670    916-7061961   

Rancho Cordova, CA   

Folsom, CA   

Elk Grove, CA   

Lehigh Acres, FL   

Port Charlotte, FL   

Mentions for Rebecca K Mchugh

Career records & work history

License Records

Rebecca K Mchugh

Address:
29 Serendipity Blvd, North Ft Myers, FL
29 Serendipity Blvd, N Ft Myers, FL
Phone:
916-8350891
Licenses:
License #: 1227712 - Active
Category: Health Care
Issued Date: Mar 30, 1981
Effective Date: Feb 11, 2006
Expiration Date: Apr 30, 2019
Type: Registered Nurse

Rebecca Mchugh resumes & CV records

Resumes

Rebecca Mchugh Photo 36

Rebecca Mchugh

Rebecca Mchugh Photo 37

Rebecca Mchugh

Rebecca Mchugh Photo 38

Rebecca Mchugh

Rebecca Mchugh Photo 39

Rebecca Mchugh

Rebecca Mchugh Photo 40

Rebecca Mchugh

Location:
United States

Publications & IP owners

Us Patents

Cd25+ Differential Markers And Uses Thereof

US Patent:
2008022, Sep 11, 2008
Filed:
Jan 31, 2008
Appl. No.:
12/023470
Inventors:
Michael Chapman Byrne - Brookline MA, US
Ethan Menahem Shevach - Rockville MD, US
Mary Collins - Natick MA, US
Rebecca Suzanne McHugh - Auburn CA, US
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Assignee:
WYETH - Madison NJ
The Government USA, as respresented by the Secretary, Department of Health - Rockville MD
International Classification:
A61K 38/00
C12N 5/06
A61P 37/00
US Classification:
514 2, 435375
Abstract:
The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25 differential markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit an autoimmune disorder or transplant rejection. Methods for determining the long term prognosis in a subject are also provided.

Cd25Markers And Uses Thereof

US Patent:
2003013, Jul 17, 2003
Filed:
Jul 12, 2002
Appl. No.:
10/194754
Inventors:
Michael Byrne - Brookline MA, US
Ethan Shevach - Rockville MD, US
Mary Collins - Natick MA, US
Rebecca McHugh - Silver Spring MD, US
Matthew Whitters - Hudson MA, US
Deborah Young - Melrose MA, US
International Classification:
A61K039/395
G01N033/567
A61K031/00
US Classification:
424/146100, 514/001000, 435/007210
Abstract:
The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25 differential markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit an autoimmune disorder or transplant rejection. Methods for determining the long term prognosis in a subject are also provided.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.